GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » EPS without NRI

3SBio, (FRA:YFK) EPS without NRI : €0.00 (TTM As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, EPS without NRI?

3SBio,'s earnings per share without non-recurring items for the six months ended in Dec. 2016 was €0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2016 was €0.00.

During the past 12 months, 3SBio,'s average earnings per share (NRI) Growth Rate was 13.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -26.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -20.90% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for 3SBio,'s EPS without NRI or its related term are showing as below:

FRA:YFK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0   Med: 0   Max: 42.2
Current: -26.7

During the past 13 years, 3SBio,'s highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.20% per year. The lowest was 0.00% per year. And the median was 0.00% per year.

FRA:YFK's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.5 vs FRA:YFK: -26.70

3SBio,'s EPS (Diluted) for the six months ended in Dec. 2016 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 was €0.00.

3SBio,'s EPS (Basic) for the six months ended in Dec. 2016 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2016 was €0.00.


3SBio, EPS without NRI Historical Data

The historical data trend for 3SBio,'s EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, EPS without NRI Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.55 - - -

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 3SBio,'s EPS without NRI

For the Biotechnology subindustry, 3SBio,'s PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio,'s PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where 3SBio,'s PE Ratio without NRI falls into.



3SBio, EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2016 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio,  (FRA:YFK) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


3SBio, EPS without NRI Related Terms

Thank you for viewing the detailed overview of 3SBio,'s EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines